Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers

Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in September ...